LYFAX — AlphaCentric Life Sciences and Healthcare Fund
Data updated: 2026-06-12
LYFAX — AlphaCentric Life Sciences and Healthcare Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $39.32M AUM · 1.71% expense ratio · 23.7% 1-yr return. From SEC regulatory filings.
LYFAX Fund Overview
LYFAX — AlphaCentric Life Sciences and Healthcare Fund is a US mutual fund managed by Mutual Fund Series Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Mutual Fund Series Trust
- Category: United States Health Care Equity
- Assets under management: $39.32M
- 1-year return: 23.7%
- Ticker: LYFAX
- SEC CIK: 0001355064
- SEC series ID: S000067055
- Share class ID: C000215731
LYFAX Holdings
Top 10 holdings of AlphaCentric Life Sciences and Healthcare Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| First American Funds Inc. | 7.72% |
| Gilead Sciences Inc. | 7.18% |
| AstraZeneca PLC | 5.63% |
| Vertex Pharmaceuticals Incorporated | 5.60% |
| Ionis Pharmaceuticals, Inc. | 3.74% |
| Insmed Inc | 3.57% |
| Incyte Corporation. | 3.41% |
| Roivant Sciences Ltd | 3.36% |
| Argenx SE | 3.33% |
| Neurocrine Biosciences Inc | 3.22% |
LYFAX Portfolio Allocation
Asset-class allocation of AlphaCentric Life Sciences and Healthcare Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 92.4% |
| Cash & Equivalents | 7.7% |
LYFAX Performance
Total returns for LYFAX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | -0.4% |
| 1 year | 23.7% |
| 3 years (annualised) | 8.2% |
| 5 years (annualised) | 4.9% |
LYFAX Risk Information
Risk metrics for LYFAX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 17.5%
LYFAX Costs and Fees
LYFAX costs about $171 per $10,000 invested per year in fund expenses.
- Net expense ratio: 1.71%
- Gross expense ratio: 2.13%
- Portfolio turnover: 164%
- Brokerage commissions: 15.33 bps of average net assets (SEC N-CEN)
LYFAX Cashflows
Over the 12 months to 2026-03, AlphaCentric Life Sciences and Healthcare Fund had net outflows of $11.05M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $57.27K |
| 2026-02 | −$118.39K |
| 2026-01 | $2.48M |
| 2025-12 | $442.74K |
| 2025-11 | $134.28K |
| 2025-10 | −$3.78M |
LYFAX Debt Constituents
No individual debt constituents are reported in AlphaCentric Life Sciences and Healthcare Fund's latest SEC N-PORT filing.
LYFAX Prospectus and SEC Filings
Official AlphaCentric Life Sciences and Healthcare Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.